Highlights of This Issue 5215

SPECIAL FEATURES

CCR Translations

5217 Overcoming Antiangiogenic Resistance
James C. Yao and Alexandria Phan
See article p. 5299

CCR Perspectives in Drug Approval

5220 The European Medicines Agency: An Overview of Its Mission, Responsibilities, and Recent Initiatives in Cancer Drug Regulation
Francesco Pignatti, Iordanis Gravanis, Ralf Herold, Spiros Vamvakas, Bertil Jonsson, and Michel Marty

Molecular Pathways

5226 Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis
Michele De Palma and Luigi Naldini

5233 Prostate Cancer Immunotherapy
Kenneth F. May, Jr., James L. Gulley, Charles G. Drake, Glenn Dranoff, and Philip W. Kantoff

Special Report

5239 SWOG Cooperative Group Biorepository Resource: Access for Scientific Research Studies
Carolyn J. Hoban, Wilbur A. Franklin, Kenneth J. Kopecky, and Laurence H. Baker

Review

5247 Prognostic Immune Markers in Non–Small Cell Lung Cancer
Kei Suzuki, Stefan S. Kachala, Kyuichi Kadota, Ronghai Shen, Qianxing Mo, David G. Beer, Valerie W. Rusch, William D. Travis, and Prasad S. Adusumilli

HUMAN CANCER BIOLOGY

5257 Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer

5268 Clonal Relationship of Classical Hodgkin Lymphoma and its Recurrences
Ellen C. Obermann, Nadine Mueller, Alexander Ruffle, Thomas Menter, Esther Mueller-Garamvoelgyi, Gieri Cathomas, Stephan Dirnhofer, and Alexandar Tzankov

5275 FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo
Rachel Sharp, Alex Pearson, Maria T. Herrera-Abreu, Damian Johnson, Alan Mackay, Jonathan C. Welti, Rachael Natrajan, Andrew R. Reynolds, Jorge S. Reis-Filho, Alan Ashworth, and Nicholas C. Turner

5287 Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis
Sharanjot Saini, Shalana Majid, Soichiro Yamamura, Laura Tabatabai, Seong O. Suh, Varahram Shahrvar, Yi Chen, Guoren Deng, Yuichiro Tanaka, and Rajvir Dahiya

CANCER THERAPY: PRECLINICAL

5299 Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition
Elizabeth Allen, Ian B. Walters, and Douglas Hanahan
See commentary p. 5217
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5311</td>
<td>In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells</td>
<td>Dharminder Chauhan, Ze Tian, Bin Zhou, Deborah Kuhn, Robert Orłowski, Noopur Raje, Paul Richardson, and Kenneth C. Anderson</td>
</tr>
<tr>
<td>5322</td>
<td>Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with P13K/mTOR Target Inhibition but with [18F]FLT Uptake</td>
<td>Thorsten Fuereder, Thomas Wanek, Pamina Pflegerl, Agnes Jaeger-Lansky, Doris Hoellmayer, Sabine Strommer, Claudia Kuntner, Friedrich Wrba, Johannes Werzowa, Michael Hejna, Markus Müller, Oliver Langer, and Volker Wacheck</td>
</tr>
<tr>
<td>5333</td>
<td>Regression of Glioma in Rat Models by Intranasal Application of Parvovirus H-1</td>
<td>Irina Kiprianova, Nadja Thomas, Ali Ayache, Manuel Fischer, Barbara Leuchs, Michièle Klein, Jean Rommelaere, and Jörg R. Schlehofer</td>
</tr>
<tr>
<td>5343</td>
<td>Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice</td>
<td>Christopher A. Klebanoff, Luca Gattinoni, Douglas C. Palmer, Pawel Muranski, Yun Ji, Christian S. Hinrichs, Zachary A. Borman, Sid P. Kerkar, Christopher D. Scott, Steven E. Finkelstein, Steven A. Rosenberg, and Nicholas P. Restifo</td>
</tr>
<tr>
<td>5353</td>
<td>PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase</td>
<td>Yi-He Ling, Miguel Aracil, Yiyu Zou, Ziqiang Yuan, Bo Lu, José Jimeno, Ana Maria Cuervo, and Roman Perez-Soler</td>
</tr>
<tr>
<td>5367</td>
<td>Targeting Src in Mucinous Ovarian Carcinoma</td>
<td>Koji Matsuo, Masato Nishimura, Justin N. Botsford-Miller, Jie Huang, Kakajan Komurov, Guillermo N. Armaiz-Pena, Mian M. K. Shahzad, Rebecca L. Stone, Ju Won Roh, Angela M. Sanguino, Chunhua Lu, Dwight D. Im, Neil B. Rosenshien, Atsuko Sakakibara, Tadayoshi Nagano, Masato Yamasaki, Takahiro Irimura, Tomohiro Takenaka, Shinji Yamasaki, and Masato Yamasaki</td>
</tr>
<tr>
<td>5379</td>
<td>Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy</td>
<td>Hifzur Rahaman Siddique, Shrawan Kumar Mishra, R. Jeffery Karnes, and Mohammad Saleem</td>
</tr>
<tr>
<td>5392</td>
<td>Induction of HLA-DP4–Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell</td>
<td>Makito Tanaka, Marcus O. Butler, Sascha Ansén, Osamu Imatuki, Alla Berezovskaya, Lee M. Nadler, and Naoto Hirano</td>
</tr>
<tr>
<td>5402</td>
<td>Resveratrol Selectively Induces DNA Damage, Independent of Smad4 Expression, in Its Efficacy against Human Head and Neck Squamous Cell Carcinoma</td>
<td>Alpna Tyagi, Mallikarjunu Ga, Takenori Takahata, Barbara Frederico, Chapla Agarwal, Sunitha Srinivasan, Rajesh Agarwal, and Robert A. Sclafani</td>
</tr>
<tr>
<td>5412</td>
<td>Role of Smac in Determining the Chemotherapeutic Response of Esophageal Squamous Cell Carcinoma</td>
<td>Yang Xu, Lanping Zhou, Jing Huang, Fang Liu, Jian Yu, Qinmin Zhan, Lin Zhang, and Xiaoang Zhao</td>
</tr>
<tr>
<td>5423</td>
<td>Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models</td>
<td>Kentaro Yamanaka, Takahito Nakahara, Tomohiro Yamauchi, Aya Kitayama, Masahiro Takeuchi, Fumiko Kiyonaga, Naoki Kaneko, and Masao Sasamata</td>
</tr>
<tr>
<td>5432</td>
<td>Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90</td>
<td>Pramod P. Mehta, Pamela Whalen, Sangita M. Baxi, Pei-Pei Kung, Shini Yamazaki, and Min-Jean Yin</td>
</tr>
</tbody>
</table>
5451 BARD1 Expression Predicts Outcome in Colon Cancer
Judith C. Sporn, Torsten Hothorn, and Barbara Jung

5463 Gene Expression Profiling of Fixed Tissues Identified Hypoxia-Inducible Factor-1α, VEGF, and Matrix Metalloproteinase-2 as Biomarkers of Lymph Node Metastasis in Hepatocellular Carcinoma
Zuo-Lin Xiang, Zhao-Chong Zeng, Jia Fan, Zhao-You Tang, Hai-Ying Zeng, and Dong-Mei Gao

5473 Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Stuart A. Grossman, Xiaobu Ye, Glenn Lesser, Andrew Sloan, Hetty Carraway, Serena Desideri, and Steven Plantadosi for the NABTT CNS Consortium

5481 A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
Wan-Teck Lim, Quan-Sing Ng, Percy Ivy, Swan-Swan Leong, Onkar Singh, Balram Chowbay, Fei Gao, Choon Huat Thng, Boon-Cher Goh, Daniel Shao-Weng Tan, Tong San Koh, Chee-Keong Toh, and Eng-Huat Tan

5490 Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

5501 Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node–Negative Cervical Cancer
Cathinka Halle, Malin Lando, Debbie Hege Svendsrud, Trevor Clancy, Marit Holden, Kolbein Sundlor, Gunnar B. Kristensen, Ruth Holm, and Heidi Lyng

5513 XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck
Immunohistochemical analysis confirmed that YM155 reduced survivin protein levels, whereas docetaxel treatment increased p34 Thr-survivin protein at G2/M mitotic arrest. Furthermore, the concomitant treatment YM155 apparently decreased the docetaxel-induced survivin upregulation below the basal level in SK-MEL-5 human malignant melanoma cell. For further details, please see Yamanaka and colleagues on page 5423 in this issue.